chrisvoncsefalvay/vaers-outcomes huggingface dataset:
No adeverse event; Patient received the bivalent booster without receiving any other COVID19 vaccine in the past; This spontaneous case was reported by an other health care professional and describes the occurrence of WRONG PRODUCT ADMINISTERED (Patient received the bivalent booster without receiving any other COVID19 vaccine in the past) and NO ADVERSE EVENT (No adeverse event) in a 31-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On 07-Sep-2022, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 07-Sep-2022, the patient experienced WRONG PRODUCT ADMINISTERED (Patient received the bivalent booster without receiving any other COVID19 vaccine in the past). On an unknown date, the patient experienced NO ADVERSE EVENT (No adeverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Patient received the bivalent booster without receiving any other COVID19 vaccine in the past) and NO ADVERSE EVENT (No adeverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adeverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Patient received the bivalent booster without receiving any other COVID19 vaccine in the past).    No concomitant medication information was provided.  No treatment medication was provided.
Varicella - Information has been received from a physician concerning a 5 year old Hispanic male with a penicillin and amoxicillin allergy who on 26 Apr 2000 was vaccinated sc with one dose of varicella virus vaccine live (lot 632612/1851J) in the left arm.  Concomitant vaccinations that same day included one dose of herpatitis a virus vaccine (msd) lot 632779/1259J).  On 02 May 2000 the patient developed a rash with approximatley 10 lesions that appeared to be chicken pox.  The patient sought unspecified medical treatment.  On 15 may 2000 the patient recovered. no further inforamtion is available.
Within 5 minutes of receiving the vaccine patient's blood pressure bottomed out and he became catatonic (like state). He was not responding to his wife or I calling his name. He was not able to move his body and just kept staring down/ off into the distance. He would come in and out as time went on he was slowing coming back to us as his BP started to elevate. He was not having trouble breathing/ we did not use any medication. Paramedics were called since patient was not responding. They evaluated him in the rescue. result of patient unknown at this time were not available to follow up when phoned on Sunday
lt upper arm around site of pneumococcal vax red swollen the size of a grapefruit w/red streak behind, hot to touch & painful;required IV ATB;
gotten 2 Fluzone HD vaccination, with no adverse event; Initial information regarding an unsolicited valid non-serious case was received from a Pharmacist via agency (Reference number- 00355247) and transmitted to Sanofi on 11-Nov-2020.  This case involves an unknown age male patient who gotten 2 fluzone high dose (HD) vaccination, with no adverse event (Off label use), while he received vaccine INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT].  Medical history, concurrent conditions, vaccination(s) and family history were not provided. Concomitant medication was unknown.  On an unknown date, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE (lot number not reported) via unknown route at an unknown administration site as prophylactic vaccination.  On an unknown date, patient gotten 2 fluzone high dose (HD) vaccination, with no adverse event (Off label use).  No laboratory data were reported.  It was not reported if the patient received a corrective treatment.  The event outcome was reported as not applicable for off label use.
Patient received her first Covid 19 Vaccine.  She has history of allergic reactions after flu vaccines and has several seasonal allergies.  She states that she spoke to her allergist prior to receiving the vaccine and was advised to receive the vaccine. At 12:30, Patient reported itching on her arms and itching in her throat.  Patient developed a cough.  No hives, no difficulty breathing, No SOB  or  No trouble speaking.   No visible rashes.  Patient given fexofenadine 60 mg per standing order at 12:40.  Patient was monitored for 30 minutes following medication and reported a relief in the itching in her throat.  She still had some itching in her arms. Patient states that she is feeling much better  Patient was instructed to proceed to the nearest ER or call 911 for worsening symptoms or difficulty breathing.  She will also contact her allergist regarding instructions for the second Covid vaccination.  Understanding verbalized.
Moderna inadvertently given to client who was 17 yr/ 9 months (< 18 y/o). - No adverse event noted
On the above-listed date, a vaccination clinic was held for staff to receive the COVID-19 booster vaccination.  On this day we had Bivalent Moderna Booster dosed vials on hand to be given to those requesting the booster dose.  At the time of the clinic, the vaccinator was operating on incorrect information that the Moderna Booster vaccination for the Bivalent vaccine was 0.25 mls rather than the new dosage of 0.5mls.  The error was not noticed until the end of the clinic.  Immediately the error was communicated to those affected.  All patients requesting so were vaccinated with the remaining 0.25 mls within 24 hours in line with the FDA and CDC recommendations for this specific error.  Two patients were contacted but requested the full dosage of the booster vaccine in the coming weeks.  Three patients were contacted and chose not to be vaccinated further.  There were no reactions noted upon follow-up.  All patients were advised to communicate with their primary care doctors and follow up with them should there be any adverse reactions.  The entire department debriefed and confirmed all new information and rehabilitated the draw-up and delivery  for all vaccinations in the future. This error was taken very seriously and all means of ensuring this is to not happen in the future were implemented.
This spontaneous report was received from a medical assistant concerning an unspecified patient of unknown age and gender. The patient's concurrent conditions and medical history were not provided. On an unknown date from 02-APR-2018 to 15-MAY-2018, the patient was vaccinated with an improperly stored dose of VARIVAX (Lot #: N021315, Exp Date: 07-AUG-2019) (Lot#: N029632, Exp Date: 23-OCT-2019) or (Lot#: N030571, Exp Date: 31-OCT-2019) for prophylaxis, which had a temperature excursion of 6.1F for 5 minutes. Previous temperature excursion was 5.9 F for 45 minutes. The digital data logger was involved in recording the temperature excursion. The vaccine was reconstituted with properly stored dose of sterile diluent (MERCK) (no more information was provided). No adverse effect was reported. No product quality complaint was involved. This is one of the several reports from the same source. Sender's Comments: US-009507513-1805USA009899:Original Case : 1805USA006787; US-009507513-1805USA009900:Original Case : 1805USA006787; US-009507513-1805USA009901:Original Case : 1805USA006787; US-009507513-1805USA009902:Original Case : 1805USA006787; US-009507513-1805USA009903:Original Case : 1805USA006787; US-009507513-1805USA009904:Original Case : 1805USA006787; US-009507513-1805USA009905:Original Case : 1805USA006787; US-009507513-1805USA009906:Original Case : 1805USA006787; US-009507513-1805USA009907:Original Case : 1805USA006787; US-009507513-1805USA009908:Original Case : 1805USA006787; US-009507513-1805USA009909:Original Case : 1805USA006787; US-009507513-1805USA009910:Original Case : 1805USA006787; US-009507513-1805USA009911:Original Case : 1805USA006787; US-009507513-1805USA009912:Original Case : 1805USA006787; US-009507513-1805USA009913:Original Case : 1805USA006787; US-009507513-1805USA009914:Original Case : 1805USA006787; US-009507513-1805USA009915:Original Case : 1805USA006787; US-009507513-1805USA009916:Original Case : 1805USA006787; US-009507513-1805USA009917:Original Case : 1805USA006787; US-009507513-1805USA009918:Original Case : 1805USA006787; US-009507513-1805USA009919:Original Case : 1805USA006787; US-009507513-1805USA009920:Original Case : 1805USA006787; US-009507513-1805USA009921:Original Case : 1805USA006787; US-009507513-1805USA009922:Original Case : 1805USA006787; US-009507513-1805USA009923:Original Case : 1805USA006787; US-009507513-1805USA009924:Original Case : 1805USA006787; US-009507513-1805USA009925:Original Case : 1805USA006787; US-009507513-1805USA009926:Original Case : 1805USA006787; US-009507513-1805USA009927:Original Case : 1805USA006787; US-009507513-1805USA006787:Original Case : 1805USA006787; US-009507513-1805USA009929:Original Case : 1805USA006787; US-009507513-1805USA009930:Original Case : 1805USA006787; US-009507513-1805USA009931:Original Case : 1805USA006787; US-009507513-1805USA009932:Original Case : 1805USA006787; US-009507513-1805USA009933.
chills; general feeling of unwellness; joint pain; tired; felt nausea; muscle pain; site of injection was sore; mild headache; This is a spontaneous report from a contactable consumer. A 63-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, Lot number: unknown) via an unspecified route of administration in the left arm on 26Feb2021 at 18:00 (at the age of 63-years-old), as a single dose for COVID-19 immunisation. The patient's medical history included pernicious anaemia, osteoarthritis, breast cancer history, osteoporosis, recovering from fall, operation from rib surgery removal of ribs & hard wiring of sternum, fibromyalgia, migraines. The patient had IVP Dye allergy. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included Bupaenorphine trans patch (MANUFACTURER UNKNOWN), duloxetine (MANUFACTURER UNKNOWN), triplex (MANUFACTURER UNKNOWN) for unknown indications received on unknown dates. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 28Feb202, the first day patient experienced vaccination site pain. On second day felt nausea, mild headache, tired & general feeling of un-wellness, had chills, muscle, joint pain plus all morning symptoms much worse. headache to point where she considered a migraine. The patient stated that, she would definitely get her second shot even if she experienced these symptoms again because she was handicapped and believe in this vaccine. Therapeutic measures taken for the adverse events unknown. The clinical outcome of the events headache, muscle soreness, muscle pain, joint pain, nausea, tiredness, joint pain, feeling unwell, chills was resolved. Information about lot/batch number cannot be obtained. No further information expected.
patient had Dizziness for few minutes while she felt floor moving , patient  was given water and orange juice and felt better and and called husband to come over to pick her up , she said she is diabetic and has history of panic attack . Patient felt better and was waiting for husband while she had a panic attack and asked to call 911 . and ambulance with paramedics came  . at the end patient felt better again in few minutes as husband arrived and went home with her and declined ambulance service .
mistakenly an extra dose of ACTHIB with no reported adverse event; Initial information received on 19-Jan-2022 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves a 2-year-old male patient who had mistakenly an extra dose of ACT-HIB with no reported adverse event while receiving vaccine HIB (PRP/T) VACCINE [ACT-HIB].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included DIPHTHERIA VACCINE TOXOID, HEPATITIS B VACCINE RHBSAG (YEAST), HIB VACCINE CONJ (MENIGOCOCCAL PROTEIN), PERTUSSIS VACCINE ACELLULAR 5-COMPONENT, POLIO VACCINE INACT 3V (VERO), TETANUS VACCINE TOXOID (VAXELIS) for Immunisation.  On 17-Jan-2022, the patient received a dose of 0.5 ml of suspect HIB (PRP/T) VACCINE (formulation, strength: unknown) lot UJ525AA, expiration: 16-Jul-2022, via intramuscular route in the right thigh as Immunisation.  On 17-JAN-2022 the patient developed a non-serious event "mistakenly an extra dose of ACT-HIB with no reported adverse event" (extra dose administered) following the administration of HIB (PRP/T) VACCINE.  It was reported" Caller states that a 2 yo was mistakenly an extra dose of ACTHIB and would like to know if it is safe? Caller would like to know how to proceed? Additional Description of event Adverse events: A 2year old patient received an extra dose of ACTHIB. Caller states that the patient had already had 3 doses of ACTHIB and was seen on 17Jan2022 where she received the 4th dose of HIB via VAXELIS. Caller states that after the patient received VAXELIS she was also given a dose of ACTHIB by mistake on the same day."  Action taken with HAEMOPHILUS TYPE B (HIB) VACCINE (ACT-HIB) was not applicable.  It was not reported if the patient received a corrective treatment for the event (mistakenly an extra dose of ACTHIB with no reported adverse event).  At time of reporting, the outcome was Unknown for the event mistakenly an extra dose of ACT-HIB with no reported adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Had varicella IZ 8/11/03 - booster IZ 7/20/07. Pt with mild varicella blisters starting on 8/25/07 - doubt rxn to vaccine.
Tingling, burning and shooting nerve impulses within all four limbs and lower legs since June 2, 2018 and symptoms are ongoing currently.
Pt received a Moderna vaccination 5 weeks ago at an outside site, unknown VAERS report done. Site was Vaccination Site. Per CDC recommendations, pt given dose #2  and w/o any significant reactions. Pt consent obtained from guardian.
Vomiting, cold chills, shaking uncontrollably; unable to move left arm for two days, extremely painful; unable to sleep, undress or dress. Abated in 48 hrs but "poor" full-range of motion for 4 days.
A report has been received from a Health Professional concerning a 4 year old, female subject, who had been receiving FLUMIST (Intranasal). FLUMIST (Intranasal) started on 21-Jan-2014. The patient received expired FLUMIST on 21-Jan-2014. The outcome of the event of EXPIRED FLUMIST ADMINISTERED is unknown. The report was considered to be non-serious by reporting health professional.
sore throat; This is a spontaneous report from a contactable consumer (Patient herself). A 25-year-old  female (non-pregnant )patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number and Expiration date was not reported), via an unspecified route of administration on 14Apr2021 (at the age of 25-year-old) as a single dose for COVID-19 immunization. The patients medical history and concomitant medications were not reported. On an unspecified date the patient reports that's she waking up with a sore throat this morning. The patient did not receive any treatment for the event. The outcome of the event was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained
patient was given a vaccine that was past the 12 hours viable; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (patient was given a vaccine that was past the 12 hours viable) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (patient was given a vaccine that was past the 12 hours viable). At the time of the report, EXPIRED PRODUCT ADMINISTERED (patient was given a vaccine that was past the 12 hours viable) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication reported. No treatment details reported.
Covid 28Jul2021; Covid 28Jul2021; Sick 3 weeks; brain fog two months; tired; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A male patient received bnt162b2 (BNT162B2), administration date Mar2021 (Batch/Lot number: unknown) as dose 2, single and administration date Feb2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 28Jul2021, outcome "unknown" and all described as "Covid 28Jul2021"; ILLNESS (non-serious) with onset 2021, outcome "unknown", described as "Sick 3 weeks"; FEELING ABNORMAL (non-serious) with onset 2021, outcome "unknown", described as "brain fog two months"; FATIGUE (non-serious) with onset 2021, outcome "unknown", described as "tired". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (28Jul2021) positive. The patient took the BOOSTER dose on Jan2022.  The lot number for bnt162b2 was not provided and will be requested during follow up.
On 02/18/2021 pt got up and said she felt like a "mac truck had run her over". Every part of her body hurt. She had chills and a fever. she was unable to eat. This lasted until Sunday, 02/21/2021. She started to feel better on Sunday and Monday. Then on Tuesday, 02/23/2021 when she woke up she was unable to walk, she did not have feeling in her hands and was in extreme pain. She was taken to her PCP. She stayed with her daughter until 02/25/2021 when she finally started to feel better. Her Cardiologist was also called and informed.
Shingles -- less than 48 hours after the 1st vaccine dose I experience my first noticeable symptom of shingles. Thurs around noon I experience a bruise like pain on my left side/back just above my waist; felt queasy. Friday still felt queasy and had the intermittent back pain; at 6pm noticed skin irritation on my stomach.  By Saturday 4/10 morning I had a rash/flat red spot in the place where I first thought I had a bruise or muscle pain plus smaller red spot on the center back and on my stomach where I felt the irritation. Sat 4/10 3:30 contacted primary care office; was seen my virtual and diagnosed with Shingles
06/15/2021 9;35 am: clot, heart attack, got a stent put in place.
12/7/17 developed body aches, weakness, fatigue, and low grade fever 99F. Ill symptoms thru 12/10/17. On 12/11/17, developed rash on upper chest, neck, face, abdomen, and back.
Fever onset 8 days post vaccine. Maculo-papular rash on nose, face, trunk starting on day 10. Examined on Day 11, and seems to be over fever, though rash still spreading.
Patient presented to clinic for booster dose of Moderna, Patient had previously received a primary dose of Janssen on 3/9/2021 and booster dose of Moderna 10/27/2021. Patient received an additional  0.25 booster dose of Moderna  on 12/27/2021 at our clinic.
6/4/10 4pm fever. 6/5/10 high WBC, fever (104.8)-Rocephin 500mg. 6/6/10 positive blood Cx, high WBC-Rocephin #2 (500mg). 6/17/10 Rocephin #3, BCX with strep anginosus (mouth flora). 6/8/10 neck with lymphadenopathy. Developed erythema. 6/9/10 IVIG for Kawasaki vs STS. 6/13/10 2nd IVIG for atypical Kawasaki.
Patient was extremely tense on arrival at clinic and curt during all interactions with us. We proceeded with vaccination and immediately upon withdrawal of the vaccine syringe needle from the patient's left deltoid the patient stood up and began yelling and cursing while slamming the wall with his fist(s?) and forearm(s?), with elbow raised at sternal or neck-height and fist above, while exclaiming that his arm hurt badly and we had "hit something" in his arm.  Due to scene safety concerns we asked him to follow us out of the clinic, and we walked out of the clinic with him. Once outside of the clinic he seemed to feel unwell and stood leaning forward, we tried to help him sit down, and he later sat with his back leaned against the wall outside. Patient was alert, PWD, nothing seemed obviously medically-abnormal aside from his reported arm pain and level of stress and agitation, vitals not attempted due to scene safety concerns. We offered him a water, which he refused.  When asked for more information while again seated, the patient elaborated that upon vaccination he'd felt an instant shooting pain in his left arm, which within less than one second had radiated up the left posterior side of his neck, and he further stated that he had a tingling sensation in his left hand only (we think he slammed that hand into the wall, with a closed fist and ulna and ulnar styloid process experiencing most of the force from impacting the wall). We were unable to inspect the hands of the patient for injury signs due to safety concerns. The patient stated he had violent impulses he was suppressing. When asked if he had previously experienced pain like this from an injection, he stated he had never experienced something like this before. We inspected his arm and it appeared that the vaccination was done in the proper area of his left deltoid, and no band-aid had been applied due scene safety concerns after the vaccine had been injected. We offered him an ice-pack for the area, which he refused.  The patient stood up, and the patient stated and/or gestured that it hurt to raise his left arm. We instructed him to try moving it and raising it more as that generally helps, and after a few attempts he seemed to be able to raise it more. He remained alert and dexterous enough to use his smartphone to take a photo of his vaccine card. He stated his arm still hurt.  The patient then chose to leave. He left our view, and we think we heard him striking something as he departed, possibly the wall, but we could not see which part of his body, if any, struck something, nor which sort of object may have been impacted, nor what sort of injury pattern could have resulted from those actions. He then apparently walked out of the area of the clinic.